In this episode of Emily Unleashed, Dr. Edward Calabrese discusses his research on hormesis and the flawed origins of the linear no-threshold (LNT) model, which has shaped regulatory policies on radiation, chemical exposure, and cancer risk for decades. The LNT model assumes that even the smallest doses of radiation or carcinogens can cause harm, with no safe level of exposure. Dr. Calabrese argues that this model is based on a flawed understanding of biology, particularly the failure to consider the body’s ability to repair damage from low-dose exposures.
Considered by many to be “Mr. Hormesis,” Dr. Calabrese has spent much of his career researching the phenomenon, which suggests that low doses of harmful substances like radiation or chemicals can actually have beneficial effects by stimulating adaptive responses in cells.
The more widely accepted LNT model traces back to the work of Hermann Muller, who won a Nobel Prize in 1946 for his research on radiation-induced mutations. Muller claimed that radiation caused mutations in a linear fashion, but Calabrese reveals that Muller’s findings were based on incomplete or flawed data, and Muller ignored or suppressed evidence that contradicted his theory, particularly the existence of DNA repair mechanisms.
The acceptance of the LNT model led to overly conservative public health policies and regulations, such as expensive cleanup efforts for contaminated sites and excessive fear of low-dose exposures. Calabrese argues that a paradigm shift that embraces hormesis could revolutionize treatments for diseases like cancer, Alzheimer’s, and Parkinson’s, and could lead to more effective and less costly public health regulations.
The full episode is available for Members of the BSI Medical Society or through premium membership of our YouTube channel.
Full Episode (Med Society)
Full Episode (YouTube)
LISTEN AS A PODCAST
The art and science of changing our collective conversation. This critical thinking project highlights the people who are smart enough to see the problem AND brave enough to expose it. The show pays homage to those who dare to challenge conventional wisdom.
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
